eMedicine Specialties > Urology > Stones

Struvite and Staghorn Calculi

Author: Maxwell Meng, MD, Associate Professor-in-Residence, Department of Urology, University of California at San Francisco
Coauthor(s): Marshall L Stoller, MD, Medical Director of Urinary Stone Center, Professor, Department of Urology, University of California at San Francisco; Thomas Minor, MD, Resident, Department of Urology, University of California San Francisco
Contributor Information and Disclosures

Updated: Nov 24, 2009

Introduction

Upper urinary tract stones that involve the renal pelvis and extend into at least 2 calyces are classified as staghorn calculi (see image below). Although all types of urinary stones can potentially form staghorn calculi, approximately 75% are composed of a struvite-carbonate-apatite matrix. These so-called struvite stones, named after the 19th-century Russian diplomat Baron von Struve (friend and mentor to 19th-century discoverer Ulex), are also known as triple-phosphate (3 cations associated with 1 anion), infection (or infection-induced), phosphatic, and urease stones. Other, less common, staghorn calculi can be composed of mixtures of calcium oxalate and calcium phosphate.

Struvite and staghorn calculi. Plain abdominal ra...

Struvite and staghorn calculi. Plain abdominal radiograph demonstrating a right staghorn calculus and a smaller left renal pelvic stone. The patient is a 72-year-old woman.

Struvite and staghorn calculi. Plain abdominal ra...

Struvite and staghorn calculi. Plain abdominal radiograph demonstrating a right staghorn calculus and a smaller left renal pelvic stone. The patient is a 72-year-old woman.


History of the Procedure

The concept that urinary tract infections play a role in lithogenesis is not new. Hippocrates noted the relationship between renal calculi and loin abscesses. In 1817, Marcet recognized the association of phosphate calculi with infection, alkaline urine, and ammoniacal urine. Not until the early 20th century did Brown propose that urea-splitting bacteria were responsible for urinary ammonia, alkalinity, and stone formation.1 The isolation of urease, the first enzyme ever purified, earned Sumner2 the Nobel Prize for Chemistry in 1946. Urease-producing organisms are listed in Etiology.

Problem

Struvite stones are invariably associated with urinary tract infections. Specifically, the presence of urease-producing bacteria, including Ureaplasma urealyticum and Proteus species (most common), Staphylococcus species, Klebsiella species, Providencia species, and Pseudomonas species, leads to the hydrolysis of urea into ammonium and hydroxyl ions. Escherichia coli does not produce urease and is not associated with struvite stone formation. Other common bacteria that have not been shown to produce urea include Citrobacter freundii, enterococci, and streptococci.

The resulting increase in ammonium and phosphate concentrations combined with the alkalotic urine (pH >7.2) is necessary for struvite and carbonate apatite crystallization. Magnesium ammonium phosphate crystals (MgNH4 PO4 •6H2 O) are admixed with carbonate apatite (Ca10 (PO4) 6•CO3) in varying proportions along with matrix. The proportion of matrix, typically low molecular weight mucoproteins, is greater than in other types of calcium-based stones and is thought to protect the bacteria from antimicrobials.

Frequency

Although calcium oxalate stones are most prevalent in the Western world, struvite calculi account for up to 30% of urinary tract stones worldwide. In the United States, 10-15% of all stones are composed of struvite. They are found more frequently in women and in persons older than 50 years, likely reflecting the population at increased risk of recurrent or persistent urinary tract infections. Accordingly, treatment of struvite stones must also address the source of these infections.

The natural history of struvite calculi mandates the complete removal of stones. First, infection stones generally grow rapidly, and any remaining stone material may serve as a nidus for future stone formation. Second, even after complete stone removal, struvite stones recur in approximately 10% of patients; if residual stones or fragments are left after treatment, recurrence rates approach 85%. Third, struvite stones are a potential source of significant morbidity. Previously, it was believed that asymptomatic struvite stones could be managed expectantly; however, studies have demonstrated that 30% of patients treated conservatively (ie, no surgery to remove stones) died of renal failure or of pyelonephritis and sepsis. Priestley and Dunn reported a 41% 5-year survival rate in patients with untreated unilateral struvite stones.3 These data underscore the importance of approaches, primarily surgical, to completely remove the stone material.

Etiology

Organisms causing struvite stones are as follows:

  • Gram-positive bacteria
    • Staphylococcus aureus
    • Staphylococcus epidermidis
    • Corynebacterium species (ie, Corynebacterium ulcerans, Corynebacterium renale, Corynebacterium ovis, Corynebacterium hofmannii, Corynebacterium murium, Corynebacterium equi)
    • Mycobacterium rhodochrous group
    • Micrococcus varians
    • Bacillus species
    • Clostridium tetani
    • Peptococcus asaccharolyticus
  • Gram-negative bacteria
    • Bacteroides corrodens
    • Helicobacter pylori
    • Bordetella pertussis
    • Bordetella bronchiseptica
    • Haemophilus influenzae
    • Haemophilus parainfluenzae
    • Proteus species (ie, Proteus mirabilis, Proteus morganii, Proteus rettgeri)
    • Providencia stuartii
    • Klebsiella species (Klebsiella pneumoniae, Klebsiella oxytoca)
    • Pasteurella species
    • Pseudomonas aeruginosa
    • Aeromonas hydrophilia
    • Yersinia enterocolitica
    • Brucella species
    • Flavobacterium species
    • Serratia marcescens
    • U urealyticum
    • Mycoplasma T-strain
  • Yeast
    • Cryptococcus species
    • Rhodotorula species
    • Sporobolomyces species
    • Trichosporon cutaneum
    • Candida humicola

Pathophysiology

Two conditions must coexist for the formation of struvite calculi. These are (1) alkaline urine (pH >7.2) and (2) the presence of ammonia in the urine. This leads to magnesium ammonium phosphate and carbonate apatite crystallization. The conversions of urea to ammonia, ammonia to ammonium, and acidification from carbon dioxide are as follows:

H2 NCONH2 + H2 O ® 2NH3 + CO2
2NH3 + H2 O ® 2NH4 + + 2OH- (increase pH >7.2)
CO2 + H2 O ® H+ + HCO3 ® 2H+ + CO32-

Presentation

The clinical presentation of patients with struvite stones can be variable. Consider struvite stones in patients with risk factors for developing urinary tract infections (eg, prior urinary diversion or urologic surgery, presence of indwelling catheters, neurogenic bladder, vesicoureteral reflux, other anatomic abnormalities).

Infections may result in pyelonephritis, pyonephrosis, or perinephric abscess. Symptoms may include flank pain classic for renal colic, fever, urinary symptoms (eg, frequency, dysuria), and hematuria (either gross or microscopic). However, struvite stones rarely manifest as a solitary ureteral stone with acute renal colic in the absence of prior intervention. Concomitant urinary obstruction and hydronephrosis may be present and can result in nausea or vomiting.

In institutionalized patients susceptible to infection stones, the ability to elicit symptoms may be limited; sepsis may be the only evidence of an underlying struvite staghorn calculus. Note that patients with struvite calculi can be asymptomatic, even when calculi occupy the entire renal collecting system. Even with progression to xanthogranulomatous pyelonephritis, 25% of patients may remain completely free of symptoms. Systemic manifestations of large struvite stones and associated chronic infection include generalized fatigue, malaise, and weight loss.

Indications

Staghorn calculi represent a less-common nephrolithiasis subgroup so named because the significant stone burden that fills the renal pelvis and calyces forms a shape on radiographs that resembles a deer's horns. Most staghorn stones in Western society are composed of struvite and can cause significant morbidity and mortality if left untreated; therefore, large struvite stones must typically be removed. Interestingly, an article investigating the structural analysis of renal calculi in northern India reported that 90% of staghorn stones were composed of oxalates.4

Unlike other urinary stones that commonly produce symptoms (eg, renal colic) that necessitate intervention, treatment of struvite stones often occurs in patients without classic signs of nephrolithiasis; this is because large staghorn calculi may not cause acute renal or ureteral dilatation and resultant pain.

Relevant Anatomy

A comprehensive discussion of renal anatomy is beyond the scope of this article; however, several points relevant to endourologic techniques are discussed.

First, the kidneys are retroperitoneal organs enclosed within several layers, including the adjacent adherent renal capsule and the renal Gerota fascia surrounding the perinephric fat. Severe renal infections associated with struvite stones may lead to abscess formation, both within the kidney and within the Gerota fascia (ie, perinephric abscess).

Second, the kidneys are intimately associated with many nearby organs. On the right side, the liver may be posterolateral to the kidney at the level of the superior pole; on the left side, the spleen resides in an analogous position. These organs may be injured during percutaneous renal access. On both sides, the colon has retroperitoneal portions that can be located posterior to the kidneys. Studies have demonstrated that retrorenal colon positions are present in up to 10% of patients.

A single kidney contains 5-14 calyces, each of which drains a renal papilla. These minor calyces may coalesce to form major calyces, all of which subsequently drain into an infundibulum. In placing percutaneous tubes into the kidney, several principles should be followed: (1) Access should not be placed through an infundibulum because of greater risks of vascular injury; (2) in all areas of the kidney (both superior and inferior), access should be gained near the fornix of the calyx; and (3) entry into a posterior calyx allows the greatest ability to examine and remove stones in the renal pelvis and in additional infundibula and calyces.

Contraindications

The presence of an active, untreated urinary tract infection is a contraindication to stone removal. Patients with struvite stones have chronic bacteriuria, and their urine is never sterilized by antibiotics alone; however, appropriate antibiotics should be administered prior to surgical intervention in an attempt to minimize the potential for sepsis during treatment. Similarly, if concomitant urinary obstruction and purulent infection exist (ie, pyonephrosis), percutaneous drainage and antibiotics are necessary before further manipulation of the stone and urinary tract.

More on Struvite and Staghorn Calculi

Overview: Struvite and Staghorn Calculi
Workup: Struvite and Staghorn Calculi
Treatment: Struvite and Staghorn Calculi
Follow-up: Struvite and Staghorn Calculi
Multimedia: Struvite and Staghorn Calculi
References
Further Reading

References

  1. Brown TR. On the Relation Between the Variety of Microorganisms and the Composition of Stone in Calculous Pyelonephritis. JAMA. 1901;36:1394-7.

  2. Sumner JB. The Isolation and Crystallization of the Enzyme Urease. J Biol Chem. 1926;69:435-41.

  3. Priestley JT, Dunn JH. Branched renal calculi. J Urol. Feb 1949;61(2):194-203. [Medline].

  4. Ansari MS, Gupta NP, Hemal AK, Dogra PN, Seth A, Aron M, et al. Spectrum of stone composition: structural analysis of 1050 upper urinary tract calculi from northern India. Int J Urol. Jan 2005;12(1):12-6. [Medline].

  5. Lam HS, Lingeman JE, Russo R, Chua GT. Stone surface area determination techniques: a unifying concept of staghorn stone burden assessment. J Urol. Sep 1992;148(3 Pt 2):1026-9. [Medline].

  6. Lewis GA, Schuster GA, Cooper RA. Dissolution of renal calculi with dicloxacillin. Urology. Oct 1983;22(4):401-3. [Medline].

  7. Al-Kohlany KM, Shokeir AA, Mosbah A, Mohsen T, Shoma AM, Eraky I, et al. Treatment of complete staghorn stones: a prospective randomized comparison of open surgery versus percutaneous nephrolithotomy. J Urol. Feb 2005;173(2):469-73. [Medline].

  8. Meretyk S, Gofrit ON, Gafni O, Pode D, Shapiro A, Verstandig A, et al. Complete staghorn calculi: random prospective comparison between extracorporeal shock wave lithotripsy monotherapy and combined with percutaneous nephrostolithotomy. J Urol. Mar 1997;157(3):780-6. [Medline].

  9. Gleason MJ, Griffith DP. Infection Stones. In: Resnick MI, Pak CY, eds. Urolithiasis: a Medical and Surgical Reference. Philadelphia, Pa: WB Saunders; 1990:134-6.

  10. Griffith DP, Osborne CA. Infection (urease) stones. Miner Electrolyte Metab. 1987;13(4):278-85. [Medline].

  11. Lam HS, Lingeman JE, Mosbaugh PG, Steele RE, Knapp PM, Scott JW, et al. Evolution of the technique of combination therapy for staghorn calculi: a decreasing role for extracorporeal shock wave lithotripsy. J Urol. Sep 1992;148(3 Pt 2):1058-62. [Medline].

  12. Lingeman JE, Lifshitz DA, Evan AP. Surgical management of urinary lithiasis. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's Urology. Vol 4. 8th ed. Philadelphia, Pa: WB Saunders; 2002:3366-3370.

  13. McDougall EM, Liatsikos EN, Dinlenc CZ. Percutaneous approaches to the Upper Urinary Tract. In: Walsh PC, Retik AB, Vaughan ED, Wein AJ, eds. Campbell's Urology. Vol 4. 8th ed. Philadelphia, Pa: WB Saunders; 2002:3320-40.

  14. Morey AF, Nitahara KS, McAninch JW. Modified anatrophic nephrolithotomy for management of staghorn calculi: is renal function preserved?. J Urol. Sep 1999;162(3 Pt 1):670-3. [Medline].

  15. Schwartz BF, Stoller ML. Nonsurgical management of infection-related renal calculi. Urol Clin North Am. Nov 1999;26(4):765-78, viii. [Medline].

  16. [Guideline] Segura JW, Preminger GM, Assimos DG, Dretler SP, Kahn RI, Lingeman JE, et al. Nephrolithiasis Clinical Guidelines Panel summary report on the management of staghorn calculi. The American Urological Association Nephrolithiasis Clinical Guidelines Panel. J Urol. Jun 1994;151(6):1648-51. [Medline].

  17. Suby HI, Albright F. Dissolution of Phosphatic Urinary Calculi by the Retrograde Introduction of a Citrate Solution Containing Magnesium. N Engl J Med. 1943;228:81-91.

  18. Wang LP, Wong HY, Griffith DP. Treatment options in struvite stones. Urol Clin North Am. Feb 1997;24(1):149-62. [Medline].

Further Reading

For further information, visit Medscape’s Stone Disease Resource Center.

Keywords

struvite calculi, staghorn calculi, triple-phosphate stones, triple phosphate stones, infection stones, urease stones, magnesium-ammonium-phosphate stones, MAP stones, extracorporeal shock-wave lithotripsy, ESWL, percutaneous nephrolithotomy, PNL, kidney stones, infection stones, infection-induced stones, phosphatic stones, urea-splitting bacteria, urease-producing organisms, Ureaplasma urealyticum, U urealyticum, Proteus, Staphylococcus, Klebsiella, Providencia, Pseudomonas, staphylococci, urinary tract stones, urinary tract infection, UTI, staghorn stones, struvite stones, struvite calculus, staghorn calculus, lithogenesis, lithotripsy, nephrolithiasis

Contributor Information and Disclosures

Author

Maxwell Meng, MD, Associate Professor-in-Residence, Department of Urology, University of California at San Francisco
Maxwell Meng, MD is a member of the following medical societies: American College of Surgeons, American Urological Association, and Society of Urologic Oncology
Disclosure: Nothing to disclose.

Coauthor(s)

Marshall L Stoller, MD, Medical Director of Urinary Stone Center, Professor, Department of Urology, University of California at San Francisco
Marshall L Stoller, MD is a member of the following medical societies: American Urological Association
Disclosure: Nothing to disclose.

Thomas Minor, MD, Resident, Department of Urology, University of California San Francisco
Thomas Minor, MD is a member of the following medical societies: American Urological Association
Disclosure: Nothing to disclose.

Medical Editor

Martha K Terris, MD, FACS, Professor, Department of Surgery, Medical College of Georgia
Martha K Terris, MD, FACS is a member of the following medical societies: American Cancer Society, American College of Surgeons, American Institute of Ultrasound in Medicine, American Urological Association, New York Academy of Sciences, and Society of University Urologists
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: eMedicine Salary Employment

CME Editor

J Stuart Wolf Jr, MD, FACS, David A Bloom Professor of Urology, Director of Division of Minimally Invasive Urology, Department of Urology, University of Michigan
J Stuart Wolf Jr, MD, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Catholic Medical Association, Endourological Society, Society for Urology and Engineering, Society of Laparoendoscopic Surgeons, Society of University Urologists, and Society of Urologic Oncology
Disclosure: Terumo Corporation Consulting fee Consulting; Gyrus-ACMI Honoraria Speaking and teaching

Chief Editor

Bradley Fields Schwartz, DO, FACS, Professor of Urology, Director, Center for Laparoscopy and Endourology, Department of Surgery, Southern Illinois University School of Medicine
Bradley Fields Schwartz, DO, FACS is a member of the following medical societies: American College of Surgeons, American Urological Association, Association of Military Osteopathic Physicians and Surgeons, Endourological Society, Society of Laparoendoscopic Surgeons, and Society of University Urologists
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.